Following a period of positive news, including the most recent contract award worth up to $62m by the Biomedical Advanced Research and Development Authority to support the development of ridinilazole, Summit has announced an underwritten public offering of 1,459,000 ADSs to raise up to $17.5m. Summit continues to make strong progress with its DMD utrophin modulation and C. difficile (CDI) programmes. The PhaseOut DMD trial completed recruitment in May, triggering a $22m milestone from Sarepta Th ....
14 Sep 2017
N+1 Singer - Summit Therapeutics - Public offering of ADSs to progress two valuable programmes
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Summit Therapeutics - Public offering of ADSs to progress two valuable programmes
Following a period of positive news, including the most recent contract award worth up to $62m by the Biomedical Advanced Research and Development Authority to support the development of ridinilazole, Summit has announced an underwritten public offering of 1,459,000 ADSs to raise up to $17.5m. Summit continues to make strong progress with its DMD utrophin modulation and C. difficile (CDI) programmes. The PhaseOut DMD trial completed recruitment in May, triggering a $22m milestone from Sarepta Th ....